GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » Equity-to-Asset

Sun Biomedical (ASX:SBN) Equity-to-Asset : 0.11 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Sun Biomedical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sun Biomedical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$1.72 Mil. Sun Biomedical's Total Assets for the quarter that ended in Dec. 2023 was A$15.09 Mil. Therefore, Sun Biomedical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.11.

The historical rank and industry rank for Sun Biomedical's Equity-to-Asset or its related term are showing as below:

ASX:SBN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11   Med: 0.88   Max: 0.98
Current: 0.11

During the past 13 years, the highest Equity to Asset Ratio of Sun Biomedical was 0.98. The lowest was 0.11. And the median was 0.88.

ASX:SBN's Equity-to-Asset is ranked worse than
81.98% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ASX:SBN: 0.11

Sun Biomedical Equity-to-Asset Historical Data

The historical data trend for Sun Biomedical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical Equity-to-Asset Chart

Sun Biomedical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.75 0.16 0.87 0.34

Sun Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.87 0.76 0.34 0.11

Competitive Comparison of Sun Biomedical's Equity-to-Asset

For the Biotechnology subindustry, Sun Biomedical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Biomedical's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sun Biomedical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sun Biomedical's Equity-to-Asset falls into.



Sun Biomedical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sun Biomedical's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=5.963/17.758
=

Sun Biomedical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1.717/15.089
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Biomedical  (ASX:SBN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sun Biomedical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Biomedical (ASX:SBN) Business Description

Traded in Other Exchanges
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines